<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593810</url>
  </required_header>
  <id_info>
    <org_study_id>ACTiVE</org_study_id>
    <nct_id>NCT04593810</nct_id>
  </id_info>
  <brief_title>Effect of Automated Closed-Loop Ventilation Versus Conventional Ventilation on Duration and Quality of Ventilation</brief_title>
  <acronym>ACTiVE</acronym>
  <official_title>Effect of Automated Closed-Loop Ventilation Versus Conventional Ventilation on Duration and Quality of Ventilation ('ACTiVE') - a Randomized Clinical Trial in Intensive Care Unit Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Marcus J. Schultz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinier de Graaf Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flevoziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouwe Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maxima Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Amstelland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabeth-TweeSteden Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diakonessenhuis, Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Policlinico San Martino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Policlinico San Matteo di Pavia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTELLiVENT-Adaptive Support Ventilation (ASV) is a fully automated closed-loop mode of&#xD;
      mechanical ventilation available on commercial ventilators. Evidence for clinical benefit of&#xD;
      INTELLiVENT-ASV in comparison to non-automated ventilation is lacking.&#xD;
&#xD;
      The ACTiVE study is an international, multicenter, randomized controlled trial in invasively&#xD;
      ventilated ICU patients with the objective to compare INTELLiVENT-ASV to conventional&#xD;
      ventilation. We hypothesise that INTELLiVENT-ASV shortens the duration of ventilation and&#xD;
      improves the quality of breathing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective&#xD;
&#xD;
      The primary objective of this trial is to compare INTELLiVENT-ASV with non-automated&#xD;
      ventilation in critically ill intensive care unit (ICU) patients with respect to ventilation&#xD;
      duration and quality of breathing.&#xD;
&#xD;
      Study design&#xD;
&#xD;
      International, multicenter, superiority randomized clinical trial in critically ill,&#xD;
      intubated and ventilated adult ICU patients with an anticipated duration of ventilation of at&#xD;
      least 24 hours.&#xD;
&#xD;
      Study population&#xD;
&#xD;
      Adult patients admitted to ICUs in the Netherlands and Italy.&#xD;
&#xD;
      Sample size calculation&#xD;
&#xD;
      The sample size is based on the hypothesis that INTELLiVENT-ASV will shorten ventilation&#xD;
      duration by 1.5 days with no changes in mortality rate. Based on previously performed studies&#xD;
      a sample of 1,200 patients (600 in each treatment group) is needed to have beta of 80% power&#xD;
      and a two-tailed alpha of 0.05, to detect a mean between-group difference of 1.5 VFD-28,&#xD;
      allowing a dropout rate of 5%. By including 1,200 patients, this study will be sufficiently&#xD;
      powered to detect differences in the co-primary endpoint, which is quality of breathing.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Within one hour of start of ventilation in the ICU, patients are randomly assigned in a 1:1&#xD;
      ratio to INTELLiVENT-ASV or non-automated ventilation. Randomization will be stratified by&#xD;
      center. As soon as possible after randomization, but within a maximum of 72 hours, deferred&#xD;
      consent is obtained from the legal representative of the patient.&#xD;
&#xD;
      INTELLiVENT-ASV In patients who are randomized to INTELLiVENT-ASV, the ventilator is switched&#xD;
      to this fully automated mode as soon possible. The sensors for end-tidal carbon dioxide&#xD;
      (ETCO2) and pulse oximetry (SpO2) are connected and activated in the ventilator. Patient's&#xD;
      gender and height are set on the ventilator and patient condition is chosen if applicable. If&#xD;
      needed, the targets zones for ETCO2 and SpO2 are adjusted. The default alarm limits are&#xD;
      accepted.&#xD;
&#xD;
      It is advised to enable QuickWean in all patients. The use of the automated Spontaneous&#xD;
      Breathing Trial (SBT) function is left to the discretion of the clinician. Each SBT result&#xD;
      will be used to check for extubation readiness.&#xD;
&#xD;
      CONVENTIONAL VENTILATION Patients who are randomized to conventional ventilation will be&#xD;
      ventilated with a mode that is not fully automated, thus standard volume controlled (VCV) or&#xD;
      pressure controlled ventilation (PCV), and pressure support ventilation (PSV), depending on&#xD;
      patient's activity. None of the following semi or fully automated modes of ventilation is&#xD;
      allowed at any time: Neurally Adjusted Ventilatory Assist (NAVA), SmartCare/PS or&#xD;
      Proportional Assist Ventilation (PAV).&#xD;
&#xD;
      In all patients who receive assist ventilation (i.e., VCV or PCV), three times a day it&#xD;
      should be checked whether the patient can accept supported ventilation (i.e., PSV); this&#xD;
      should also be tried when the patient shows respiratory muscle activity during assist&#xD;
      ventilation, or in case of patient-ventilator asynchrony.&#xD;
&#xD;
      Patients can be subjected to SBTs using either a T-piece or ventilation with minimal support&#xD;
      (pressure support level &lt; 10 cm H2O). An SBT is deemed successful when the following criteria&#xD;
      are met for at least 30 minutes, i.e., respiratory rate &lt; 35/min, peripheral oxygen&#xD;
      saturation &gt; 90%, increase &lt; 20% of heart rate and blood pressure, and no signs of anxiety&#xD;
      and diaphoresis. Each SBT result will be used to check for extubation readiness.&#xD;
&#xD;
      In both groups patients are extubated if standard extubation criteria are fulfilled, i.e.,&#xD;
      normal body temperature, patient awake and responsive/cooperative, adequate cough reflex,&#xD;
      adequate oxygenation and hemodynamically stable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days and alive at day 28</measure>
    <time_frame>first 28 days after start of ventilation</time_frame>
    <description>The number of days from day 1 to day 28 the patient is alive and breathes without assistance of the mechanical ventilator, if the period of unassisted breathing lasted at least 24 consecutive hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of breathing</measure>
    <time_frame>up to 48 hours after inclusion</time_frame>
    <description>Time spent within predefined zones of optimal ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilation</measure>
    <time_frame>first 28 days after start of ventilation</time_frame>
    <description>Duration of ventilation in survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>first 90 days after start of ventilation</time_frame>
    <description>Length of stay in the intensive care unit and in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>first 90 days after start of ventilation</time_frame>
    <description>Any death during ICU-, hospital-stay and within 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary complications</measure>
    <time_frame>daily until ICU discharge or day 28</time_frame>
    <description>Development of ARDS, severe hypoxemia, severe hypercapnia, severe atelectasis, pneumothorax and pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue therapies for severe hypoxemia or severe atelectasis</measure>
    <time_frame>daily until ICU discharge or day 28</time_frame>
    <description>Incidence of use of rescue therapies for severe hypoxemia or severe atelectasis: recruitment maneuver, prone positioning, bronchoscopy for opening atelectasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extubation failure</measure>
    <time_frame>daily until ICU discharge or day 28</time_frame>
    <description>Extubation with need for reintubation within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal inspiratory pressure (MIP)</measure>
    <time_frame>within 24 hours after extubation</time_frame>
    <description>Maximal inspiratory pressure measured after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire</measure>
    <time_frame>day 28 after start of ventilation</time_frame>
    <description>The European Quality of life 5 Dimensions 5 Levels questionnaire (EQ-5D-5L) is used to assess health-related quality of life status in adults. It consists of five dimensions (Mobility, Self-care, Usual activities, Pain &amp; discomfort, Anxiety &amp; depression), each of which has five severity levels (from 1 to 5) that are described by statements appropriate to that dimension. Higher values mean worse quality of life. The evaluation includes a visual analogue scale to quantitative measure the overall health status. This scale has a range from 0 to 100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Ventilator-free Days</condition>
  <condition>Quality of Breathing</condition>
  <arm_group>
    <arm_group_label>INTELLiVENT-ASV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of INTELLIVENT-ASV after intubation and during all mechanical ventilation in the ICU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of conventional ventilation after intubation and during all mechanical ventilation in the ICU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>INTELLiVENT-ASV</intervention_name>
    <description>INTELLiVENT-ASV is activated as soon possible. The sensors for ETCO2 and SpO2 are connected and activated. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.</description>
    <arm_group_label>INTELLiVENT-ASV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CONVENTIONAL VENTILATION</intervention_name>
    <description>Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity. None of the semi or fully automated modes of ventilation is allowed at any time.</description>
    <arm_group_label>Conventional ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  admission to one of the participating ICUs&#xD;
&#xD;
          -  intubated and receiving invasive ventilation&#xD;
&#xD;
          -  anticipated duration of ventilation of at least 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age below 18 years&#xD;
&#xD;
          -  patients with suspected or confirmed pregnancy&#xD;
&#xD;
          -  invasive ventilation &gt; 1 hour in the ICU&#xD;
&#xD;
          -  invasive ventilation &gt; 6 hours in the operating room or emergency department directly&#xD;
             preceding the current ICU admission&#xD;
&#xD;
          -  participation in another interventional trial using similar endpoints&#xD;
&#xD;
          -  after recent pneumectomy or lobectomy&#xD;
&#xD;
          -  morbid obesity (body mass index &gt; 40 kg/m2)&#xD;
&#xD;
          -  premorbid restrictive pulmonary disease (evidence of chronic interstitial infiltration&#xD;
             on chest radiographs)&#xD;
&#xD;
          -  unreliable pulse oximetry, e.g., patients with carbon monoxide poisoning&#xD;
&#xD;
          -  any neurologic diagnosis that can prolong duration of mechanical ventilation, e.g.,&#xD;
             Guillain-Barr√© syndrome, high spinal cord lesion or amyotrophic lateral sclerosis,&#xD;
             multiple sclerosis, or myasthenia gravis&#xD;
&#xD;
          -  patients receiving or planned to receive veno-venous, veno-arterial or arterio-venous&#xD;
             extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          -  previous randomized in this study&#xD;
&#xD;
          -  no informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janneke Horn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Intensive Care, Academic Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederique Paulus, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Intensive Care, Academic Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcus J Schultz, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Intensive Care, Academic Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michela Botta, MD</last_name>
    <phone>+31626198315</phone>
    <email>m.botta@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anissa M Tsonas, MD</last_name>
    <phone>+31614927716</phone>
    <email>a.m.tsonas@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genua</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paolo Pelosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo Fondazione IRCCS</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Mojoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Amstelland</name>
      <address>
        <city>Amstelveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center, Intensive Care</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janneke Horn, MD, PhD</last_name>
      <email>j.horn@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwen Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maxima Medical Center</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden UMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis, Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 11, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Marcus J. Schultz</investigator_full_name>
    <investigator_title>Prof. Dr. Marcus J. Schultz</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04593810/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

